CardioVascular Business Overview

CardioVascular accounted for $2.1 billion, or 16%, of Medtronic's $13.5 billion in revenue in FY2008.

FY2008 Revenue
CardioVascular accounted for $2.1 billion, or 16%, of Medtronic's $13.5 billion in revenue in FY2008.

CardioVascular is Medtronic's third-largest business. As hospitals and healthcare organizations increasingly encourage collaboration between cardiovascular specialties, Medtronic continues to serve as a key resource. Our therapies span the major specialties of interventional cardiology, cardiac surgery, and vascular surgery.

Our products, developed in collaboration with leading physicians, are used to reduce the potentially debilitating effects of coronary, aortic, and structural heart disease. These products include:

  • Angioplasty technologies to treat arteries that are blocked by atherosclerotic plaque and restore blood flow to the heart. Our highest-profile product is the Endeavor® drug-eluting coronary stent.1
  • Stent grafts2 to treat aortic aneurysms. Their rupture leads to more than 15,000 deaths in the United States alone. Through our collaboration with the National Aneurysm Alliance in the United States, we helped gain Medicare coverage for abdominal aortic aneurysm (AAA) screenings to help detect this potentially life-threatening condition, which can be treated with our minimally invasive therapies.
  • Heart valves3 and valve repair technology to treat congenital heart defects and valve disease. We also continually work to develop minimally invasive approaches to traditional full open-chest heart surgery for valve replacement and repair.
  • Open-heart and coronary bypass graft products to restore blood flow to the heart. We're continually making our products simpler for surgeons to use and easier on patients. For example, we're now on the 10th generation of our Octopus® Stabilizer,4 which holds arteries in place so a surgeon can operate on a beating heart.

Medtronic Educational Program

Our EDGE (U.S.) and Academia (Europe) programs offer a variety of multi-faceted training events designed to expand the skills of cardiac surgeons and enable them to thrive as cardiovascular specialties draw from one another to improve patient care. Through the programs, surgeons work with leading experts in many areas, including virtual catheter lab training, complex mitral repair, minimally invasive valve surgery, robotic surgical techniques, and beating heart strategies.

References

  1. Important Safety Information for Endeavor® Drug-Eluting Coronary Stent
  2. Important Safety Information for Stent Grafts (Aortic Aneurysms)
  3. Important Safety Information for Heart Valve Repair and Replacement
  4. Important Safety Information for Octopus® Stabilizer
Last updated: 3 Nov 2008

Section Navigation

Additional information

NYSE (MDT)

United States